SQUAMOUS NON-SMALL-CELL LUNG CANCER
Clinical trials for SQUAMOUS NON-SMALL-CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS NON-SMALL-CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for SQUAMOUS NON-SMALL-CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to outperform standard lung cancer treatment
Disease control Not yet recruitingThis study is testing if a new drug, HB0025, works better than the current standard drug, pembrolizumab, when each is given with chemotherapy. It is for adults with advanced or metastatic squamous non-small cell lung cancer who have not had prior treatment. About 480 participants…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Custom vaccine tailored to Patient's tumor enters first human test
Disease control Not yet recruitingThis is a first-in-human safety study for a personalized cancer vaccine called PANDA-VAC. It will be given alongside the immunotherapy drug pembrolizumab to 6 patients with advanced squamous cell lung cancer or head and neck cancer. The vaccine is custom-made for each patient bas…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Feb 20, 2026 14:37 UTC